What is the appropriate evaluation and management for a 16‑year‑old female with elevated DHEA‑Sulfate (dehydroepiandrosterone sulfate), elevated total testosterone, elevated free testosterone, and vitamin D deficiency?

Evaluation and Management of Hyperandrogenism in a 16-Year-Old Female

This 16-year-old requires immediate systematic evaluation to exclude life-threatening androgen-secreting tumors, followed by assessment for PCOS and non-classic congenital adrenal hyperplasia, while simultaneously treating her vitamin D deficiency.

Immediate Priority: Exclude Androgen-Secreting Neoplasms

While PCOS is statistically most likely, the elevated testosterone (62 ng/dL) and DHEA-S (308 µg/dL) mandate exclusion of ovarian or adrenal tumors, which carry significant morbidity and mortality if missed 1.

Critical Clinical Assessment Required:

• Rapidity of symptom onset: Virilization developing over weeks to months suggests tumor
• Degree of virilization: Clitoromegaly, voice deepening, male-pattern baldness, or increased muscle mass are red flags
• Menstrual pattern: Document presence/absence of oligomenorrhea or amenorrhea
• Physical stigmata: Look specifically for acanthosis nigricans, central obesity, hirsutism severity, acne distribution
• Family history: Type 2 diabetes, PCOS, or ethnic background suggesting CAH risk (Ashkenazi Jewish, Hispanic, Slavic populations)

Diagnostic Algorithm

Step 1: Complete the Hyperandrogenism Workup

Based on Endocrine Society guidelines 1, obtain:

• Early morning 17-hydroxyprogesterone (follicular phase, days 4-10 if cycling): Essential to exclude non-classic congenital adrenal hyperplasia, particularly given elevated DHEA-S. This is especially critical if she has high-risk ethnicity 1

• Pelvic ultrasonography: Mandatory to detect ovarian neoplasm or polycystic ovarian morphology 1

• Prolactin level: Exclude hyperprolactinemia as a cause of menstrual irregularity 1

• Pregnancy test: If amenorrheic 1

• Consider Cushing's syndrome screening: If clinical features present (striae, easy bruising, proximal weakness, moon facies) 1

Step 2: Interpret Testosterone and DHEA-S Levels

Important caveat: While total testosterone >250 ng/dL (8.7 nmol/L) has been proposed as a tumor threshold, this has poor positive predictive value (only 9%) 2. Her testosterone of 62 ng/dL is elevated but below the traditional "tumor threshold." However, clinical presentation trumps arbitrary cutoffs—rapid virilization warrants imaging regardless of absolute values 2.

The DHEA-S of 308 µg/dL is elevated but well below the 600 µg/dL threshold traditionally associated with adrenal tumors. Notably, no adrenal tumors were found in patients with DHEA-S <600 µg/dL in a large series 2. However, elevated DHEA-S still requires 17-hydroxyprogesterone measurement to exclude CAH 1.

Step 3: If Initial Workup is Negative

If pelvic ultrasound, 17-hydroxyprogesterone, and prolactin are normal, and she has menstrual irregularity or polycystic ovaries on ultrasound, she meets diagnostic criteria for PCOS 1.

Additional testing may include:

• Fasting glucose and lipid profile (assess metabolic syndrome risk)
• Consider ACTH stimulation test if 17-OHP is borderline (200-1000 ng/dL)
• Adrenal CT scan only if clinical suspicion for tumor persists despite normal DHEA-S

Management of Vitamin D Deficiency

Her vitamin D level of 24 ng/mL represents insufficiency (defined as 21-29 ng/mL), approaching deficiency (<20 ng/mL) 3.

Treatment Recommendation:

For a 16-year-old, the Endocrine Society recommends at least 600-1000 IU/day of vitamin D3 to maintain sufficiency, but 1500-2000 IU/day is suggested for those at risk or with documented insufficiency 3. Given her current level of 24 ng/mL:

• Prescribe vitamin D3 2000 IU daily to achieve target 25(OH)D >30 ng/mL 3
• Recheck 25(OH)D level in 3 months
• Consider higher loading doses (50,000 IU weekly for 8 weeks) if she has malabsorption or poor compliance anticipated

Important note: While one study suggested DHEA/vitamin D combination therapy may benefit thyroid autoimmunity 4, this is not relevant to her presentation and DHEA supplementation is not indicated for adolescent hyperandrogenism.

Clinical Context and Pitfalls

Common Pitfalls to Avoid:

1. Assuming PCOS without excluding CAH: The combination of elevated DHEA-S and testosterone in an adolescent mandates 17-OHP measurement, especially in high-risk ethnic groups 1

2. Over-reliance on DHEA-S cutoffs: While very high DHEA-S (>600 µg/dL) suggests adrenal tumor, moderately elevated levels (like 308 µg/dL) are common in PCOS and premature adrenarche 5, 6

3. Missing rapid progression: Serial clinical assessment is critical—worsening virilization despite "reassuring" hormone levels warrants imaging 1, 2

4. Ignoring metabolic consequences: PCOS in adolescence predicts future metabolic syndrome, type 2 diabetes, and cardiovascular disease—early intervention improves long-term outcomes 1

Nuances in Adolescent Hyperandrogenism:

Research shows that high DHEA-S in prepubertal girls (around age 7) predicts earlier thelarche, pubarche, and menarche, with mildly elevated androgens throughout puberty 5. However, this does not typically result in polycystic ovarian morphology immediately post-menarche 5. Your patient at age 16 is beyond this early pubertal window, making PCOS or CAH more likely than simple premature adrenarche.

Next Steps Summary

Immediate actions:

1. Obtain early morning 17-hydroxyprogesterone (follicular phase)
2. Order pelvic ultrasound
3. Check prolactin
4. Start vitamin D3 2000 IU daily
5. Document menstrual pattern, hirsutism severity, and timeline of symptom development

If workup confirms PCOS: Address metabolic screening (glucose, lipids), consider combined oral contraceptives for menstrual regulation and androgen suppression, lifestyle modification for weight management if applicable, and metformin if insulin resistance present.

If 17-OHP elevated: Refer to pediatric endocrinology for ACTH stimulation testing and potential genetic testing for CYP21A2 mutations 1.